Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases

被引:312
作者
Grimmler, Matthias
Wang, Yuefeng
Mund, Thomas
Cilensek, Zoran
Keidel, Eva-Maria
Waddell, M. Brett
Jaekel, Heidelinde
Kullmann, Michael
Kriwacki, Richard W.
Hengst, Ludger
机构
[1] St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA
[3] Univ Innsbruck, Bioctr, Div Med Biochem, A-6020 Innsbruck, Austria
[4] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[5] Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38105 USA
关键词
D O I
10.1016/j.cell.2006.11.047
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
P27(Kip1) controls cell proliferation by binding to and regulating the activity of cyclin-dependent kinases (Cdks). Here we show that Cdk inhibition and p27 stability are regulated through direct phosphorylation by tyrosine kinases. A conserved tyrosine residue (Y88) in the Cdk-binding domain of p27 can be phosphorylated by the Src-family kinase Lyn and the oncogene product BCR-ABL. Y88 phosphorylation does not prevent p27 binding to cyclin A/Cdk2. Instead, it causes phosphorylated Y88 and the entire inhibitory 3(10)-helix of p27 to be ejected from the Cdk2 active site, thus restoring partial Cdk activity. Importantly, this allows Y88-phosphorylated p27 to be efficiently phosphorylated on threonine 187 by Cdk2 which in turn promotes its SCF-Skp2-dependent degradation. This direct link between transforming tyrosine kinases and p27 may provide an explanation for Cdk kinase activities observed in p27 complexes and for premature p27 elimination in cells that have been transformed by activated tyrosine kinases.
引用
收藏
页码:269 / 280
页数:12
相关论文
共 42 条
[1]
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27 Kip1 degradation and proliferation of chronic myelogenous leukemia cells [J].
Andreu, EJ ;
Lledó, E ;
Poch, E ;
Ivorra, C ;
Albero, MP ;
Martínez-Climent, JA ;
Montiel-Duarte, C ;
Rifón, J ;
Pérez-Calvo, J ;
Arbona, C ;
Prósper, F ;
Pérez-Roger, I .
CANCER RESEARCH, 2005, 65 (08) :3264-3272
[2]
p27 as a target for cancer therapeutics [J].
Blain, SW ;
Scher, HI ;
Cordon-Cardo, C ;
Koff, A .
CANCER CELL, 2003, 3 (02) :111-115
[3]
Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) with cyclin A-Cdk2 and cyclin D2-Cdk4 [J].
Blain, SW ;
Montalvo, E ;
Massague, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (41) :25863-25872
[4]
Deregulated degradation of the cdk inhibitor p27 and malignant transformation [J].
Bloom, J ;
Pagano, M .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) :41-47
[5]
Boyle WJ., 1991, METHOD ENZYMOL, V201, P110
[6]
The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts [J].
Cheng, MG ;
Olivier, P ;
Diehl, JA ;
Fero, M ;
Roussel, MF ;
Roberts, JM ;
Sherr, CJ .
EMBO JOURNAL, 1999, 18 (06) :1571-1583
[7]
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2 [J].
Chu, Isabel ;
Sun, Jun ;
Arnaout, Angel ;
Kahn, Harriette ;
Hanna, Wedad ;
Narod, Steven ;
Sun, Ping ;
Tan, Cheng-Keat ;
Hengst, Ludger ;
Slingerland, Joyce .
CELL, 2007, 128 (02) :281-294
[8]
Altered p27Kip1 phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor β-mediated G1 arrest [J].
Ciarallo, S ;
Subramaniam, V ;
Hung, W ;
Lee, JH ;
Kotchetkov, R ;
Sandhu, C ;
Milic, A ;
Slingerland, JM .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (09) :2993-3002
[9]
v-Abl utilizes multiple mechanisms to drive G1/S progression in fibroblasts [J].
Coutts, M ;
Zou, XM ;
Calame, K .
ONCOGENE, 2000, 19 (06) :801-809
[10]
DanhauserRiedl S, 1996, CANCER RES, V56, P3589